Metastatic spread to a percutaneous gastrostomy site from head and neck cancer: case report and literature review.

BACKGROUND: The placement of percutaneous endoscopic gastrostomy tubes is a common procedure in patients with head and neck cancer who require adequate nutrition because of the inability to swallow before or after surgery and adjuvant therapies. A potential complication of percutaneous endoscopic gastrostomy tubes is the metastatic spread from the original head and neck tumor to the gastrostomy site.
METHODS: This is a case of a 59-year-old male with a (T4N2M0) Stage IV squamous cell carcinoma of the oropharynx who underwent percutaneous endoscopic gastrostomy tube placement at the time of his surgery and shortly thereafter developed metastatic spread to the gastrostomy site. A review of the published literature regarding the subject will be made.
RESULTS: Twenty-nine cases of percutaneous endoscopic gastrostomy site metastasis occurring in patients with head and neck cancer have been previously reported in the literature. The pull-through method of gastrostomy tube placement had been used in our patient as well as in the majority of the other cases reviewed in the literature.
CONCLUSION: The metastatic spread of head and neck cancer to the percutaneous endoscopic gastrostomy site is a very rare occurrence. The direct implantation of tumor through instrumentation is the most likely explanation for metastasis; however, hematogenous seeding is also a possibility. To prevent this rare complication, other techniques of tube insertion need to be considered.

INTRODUCTION

Gauderer et al[1] first described the technique of percutaneous endoscopic gastrostomy (PEG) in 1980. It was originally introduced as an alternative method to conventional open surgical gastrostomy for nutritional support in patients with head and neck cancer. It is considered to be a safer procedure, with a lower complication rate, is less invasive, generally well tolerated, and more cost effective.[2] Percutaneous endoscopic gastrostomy has been shown to improve nutritional status and the quality of life in these patients.[3-5]

Complications of percutaneous endoscopic gastrostomy are relatively uncommon, but include local infection, hemorrhage, dislodgment, peritonitis, bowel perforation, and aspiration pneumonia.[6] Another rare complication that appears to be becoming more prevalent is the meta-static implantation of tumor at the PEG tube site. The first case of gastric and abdominal wall metastasis secondary to PEG placement in a patient with head and neck cancer was reported in 1989.[7] Since then, 29 similar cases of tumor implantation at the PEG site have been reported. We report another case of tumor implantation at the PEG site from squamous cell cancer (SCC) of the head and neck. A review of the literature helped to determine the possible mechanism of spread.

CASE REPORT

The patient is a 59-year-old male with a history of alcoholism and tobacco abuse. In March 2004, he was diagnosed with a (T4N2M0) Stage IV squamous cell carcinoma (SCC) of the right soft palate, tonsilllar fossa, retromolar trigone, and base of the tongue. He underwent wide resection that included half of the soft palate, the tonsillar region, the retromolar trigone, and about 40% of the base of the tongue. He also underwent a modified neck dissection. To cover the defect, a skin/subcutaneous free flap from the abdomen was utilized. A tracheostomy and PEG tube placement were performed at the time of the original surgery. Postoperatively, the patient had problems with delirium tremens but was able to be discharged on day 7 tolerating tube feedings. All surgical margins were free of tumor involvement. The patient had 2 positive nodes in the right neck, 1 with extracapsular spread, and both lymphovascular and perineural invasion had occurred within the specimen. The patient subsequently underwent 34 treatments of radiation therapy (XRT).

In April 2004, the patient also underwent mandibular odontectomy, alveolectomy, and minor revision of the free flap at the alveolar process. Close to 1 month after insertion of the PEG tube, the patient stated he noticed some granulation tissue forming around the tube site. This progressed rapidly, but the patient neglected to seek medical attention. In July 2004, the patient was referred by his family practitioner with a large 4-cm fungating mass around his tube site. Within 3 weeks, the mass reached a size of 9 cm in diameter (. An incisional biopsy was obtained that revealed SCC, and it was felt that this came from the patient's original head and neck cancer. Upper endoscopy was performed that showed the tumor around the bumper or mushroom within the stomach (. Further evaluation by computed tomography (CT) showed a large mass extending through the abdominal wall (. Metastatic workup to include CT of the head, neck, chest, and abdomen were negative, except for the mass in the abdominal wall and stomach. Radiation-oncology consultation was obtained, and the patient subsequently received 4500 rads, 25 fractions to the abdominal wall. A significant reduction in the size of the mass was obtained. Several weeks later following radiation therapy, the patient had a CT scan that did not show any residual disease. An en bloc resection of the abdominal wall around the PEG to include a wedge re-section of the stomach was performed. Margins were clear, and no residual tumor was detected. The abdominal wall was repaired with Dual Mesh. The patient was discharged 5 days later tolerating a soft puree diet. The patient did well initially; on follow-up, however, exactly 1 year later, from the time of the patient's original head and neck surgery, he developed local recurrence to the jaw. The patient is presently in hospice care.

Large exophytic lesion around the percutaneous endoscopic gastrostomy tube.

Endoscopically visible tumor around the percutaneous endoscopic gastrostomy tube bumper.

Computed tomographic scan of the abdomen revealing transabdominal extent of the tumor.

DISCUSSION

Since its introduction in 1980, PEG has become increasingly popular after surgery, and radiotherapy for improving patient's nutritional status and reducing the duration of the hospital stay.[1] It is also the preferred method for feeding patients with severe facial trauma and dysphagia as a result of advanced neurological disease and more recently has been used successfully in patients who require prolonged gastrointestinal decompression.[2] Surgical or open gastrostomy has the disadvantage of requiring a laparotomy, and most studies have shown it to be associated with more complications than PEG.[8,9]

Several methods have been described for the percutaneous endoscopic insertion of the gastrostomy tube, of which the Ponski-Gauderer pull method is the most widely used.[1] The pull-through method involves passing the endoscope through the mouth into the stomach. An angiocatheter is introduced through the abdominal wall into the insufflated stomach under direct visualization. A wire is then passed through the angiocatheter, snared endoscopically, and pulled through the patient's mouth. The gastrostomy tube is then attached to the end of the wire and pulled back through the mouth and esophagus into the stomach and out through the abdominal wall. Another less popular technique, known as the “push-through” or “introducer” technique uses the Seldinger method to directly place the tube through the abdominal wall into the stomach that has been insufflated by way of the esophagus.[10] This technique does not require passage of the gastrostomy tube over the pharynx.

The reported complication rate for PEG is about 5% compared with about 10% for open gastrostomy, and the reported procedure-related mortality rate is less than 1% compared with about 4% for open gastrostomy.[8,9] Complications of PEG include aspiration pneumonia and airway compromise, hemorrhage, tube dislodgement, abdominal wall infection, intraperitoneal leakage and peritonitis, gastroesophageal reflux, dyspnea, transient pneumoperitoneum, tube blockage, pain and infection around the tube site, and formation of granulation tissue.[2] A rare but increasingly reported complication in patients with head and neck cancer is the metastatic spread of SCC to the PEG tube site.

The reported incidence of metastatic neoplasms to the stomach have been 0.7% to 2%.[11-13] In autopsy findings by Antler et al,[14] the incidence of lung cancer metastasizing to the stomach was as high as 9%.

The spread of cancer to a gastrostomy stoma was first reported in 1971 by Alagaratnam,[15] who performed the procedure in an open manner. Since 1989, 29 cases have been reported of metastatic seeding from the upper aerodigestive tract to the PEG site. A total of 29 of these patients including our patient had squamous cell carcinoma and 1 had adenocarcinoma (.[2,7,15-39]

It appears that the pull method was used in all these cases. In our case, the patient described tumor developing around the PEG tube 1 month after insertion, but the mean time to PEG site implantation in previously reported cases was 8 months (range, 2 to 17). It is also interesting to note that almost all cases involved advanced (Stage III, IV) SCC of the head and neck region. The exception to that is an adenocarcinoma of the distal esophagus.[16]

Various theories exist concerning the mechanism of spread of the tumor to the PEG site, which include the direct implantation at the time of PEG placement, hematogenous or lymphatic spread, and the possibility of shedding of tumor cells into the gastrointestinal tract from the original head and neck cancer. No controlled experiments have been done to determine whether a particular PEG technique or simply the trauma secondary to the gastrostomy is responsible.[24]

One hypothesis is that the pull method that was used in all reportable cases may implant or seed malignant cells along the path where instruments have injured the tissue.

Tumor cells from the oropharynx coat and contaminate the bumper of the PEG tube as it is pulled through. This theory is also supported by cases reported by Sharma et al[18] and Potochny et al,[19] as well as others (.[20-23,27]

In an effort to clarify the mechanism of spread, Douglas et al used a tumor kinetic model and concluded that direct implantation of cells is more likely than hematogenous spread in patients whose metastasis appears within 12 months of PEG placement.[25,26] In a review of cases since 1989, it was noted that a substantial proportion of patients had PEG metastasis develop at a very short interval after the procedure, as early as 2 months.[25] Our patient noticed the tumor within 1 month but failed to seek medical attention.

A study by Kodama et al[40] reported that surgical stress might cause an increase in tumor metastasis because high levels of serum cortisol after a surgical procedure may induce morphological changes, both in the capillary lumen and on the tumor cell surface, that may facilitate retention of tumor cells. These results are consistent with the possibility that direct implantation causes tumor metastasis.[28]

Another theory is that metastasis at the gastrostomy stomata is related to either hematogenous or lymphatic spread of tumor cells.[17,26,29,41,42] This hypothesis is in agreement with accepted ideas regarding the mechanism of cancer metastasis.[43] In the majority of cases, the primary tumor had known lymph node invasion (before gastrostomy tube placement), and in over half the cases, distant metastases were discovered previously or concurrently with the stomal metastasis.[17] This implies that tumor cells were circulating in the lymphatic channels and blood stream.

CONCLUSION

The exact mechanism of gastric and abdominal wall metastasis in patients with PEG placement still remains unclear and controversial. Since 1989, almost every year a case of metastatic implantation at the PEG tube site for head and neck cancer has been reported. PEG placement by the pull method appears to remain the preferred or standard procedure for patients with head and neck cancer in spite of the overwhelming evidence not to use this method. Special precautions must be taken during the procedure to minimize the disruption of tumor cells. It is our suggestion that an alternative to the pull method should be considered in this select group of patients.

Table 1.

Cases of Metastasis to Gastrostomy Site

Reference	Cancer Histology and Stage	Primary Tumor Location	Insertion Method	Metastasis Interval (mos.)	Concurrent Metastasis
1977 Alagaratnam[15]	SCC, 4	Oropharynx, Larynx	Open	24	None
1989 Preyer[7]	SCC, 4	Nasopharynx	Pull	3	Lungs
1991 Bushnell[30]	SCC, 4	Larynx, Lungs	Pull	15	Skin
1992 Huang[31]	SCC, 4	Oropharynx, Larynx	Pull	6	Not reported
1993 Heinbokel[16]	Adenoca, 4	Gastric cardia esophagus	Pull	2	Not reported
1993 Laccourreye[20]	SCC, 4	Hypopharynx	Pull	11	Liver
1993 Massoun[32]	SCC, 4	Oropharynx	Pull	4	Lungs
1993 Meurer[29]	SCC, 4	Oropharynx, Larynx	Pull	12	Lungs
1993 Meurer[29]	SCC, 4	Oropharynx	Pull	15	Lungs
1994 Schiano[33]	SCC, 4	Hypopharynx	Pull	4	Not reported
1994 Sharma[18]	SCC, 4	Oropharynx	Pull	6	None
1995 Becker[34]	SCC, 4	Hypopharynx	Pull	3	Lungs
1995 Becker[34]	SCC, 3	Cervical Esophagus	Pull	5	Local relapse
1995 Lee[27]	SCC, 4	Oropharynx	Pull	13	Gastric ligaments
1998 Van-Erpecum[21]	SCC, 4	Hypopharynx	Pull	2–10	None
1995 Wilson[35]	SCC, 4	Hypopharynx	Pull	Not reported	Not reported
1997 Schneider[22]	SCC, 4	Oropharynx	Pull	10	None
1997 Thorburn[23]	SCC, 4	Hypopharynx, Larynx	Pull	11	Not reported
1998 Potochny[19]	SCC, 4	Hypopharynx	Pull	9	None
1999 Deinzer[36]	SCC, 3	Proximal Esophagus	Pull	3	Not reported
1999 Hosseini[37]	SCC, 2/3	Distal Esophagus	Pull	2	None
2000 Brownl[7]	SCC, 3	Mid Esophagus	Pull	9	Lungs, spine
2000 Peghini[38]	SCC, 4	Tongue	Pull	9	Skin, Colon, Bone
2000 Douglas[25]	SCC, 4	Tonsillar Fossa	Pull	3.6	None
1996 Lauvin[39]	SCC, 4	Esophagus	Pull	4	Not reported
2001 Sinclair[28]	SCC, 3	Tongue	Pull	5	Axillary Nodes
2001 Cossentino[26]	SCC, 4	Tongue	Pull	8	Lung
2001 Cossentino[26]	SCC, 2	Tongue	Pull	9	None
2002 Anath[2]	SCC, 4	Floor of mouth	Pull	3	None
2003 Thakore[24]	SCC, 4	Larynx	Pull	Unable to determine	Lungs, Bone, Skin, Brain
2005 Mincheff	SCC, 4	Oropharynx	Pull	1	None

SCC = small cell carcinoma.